Patent application number | Description | Published |
20090142341 | Mutated pseudomonas exotoxins with reduced antigenicity - The invention provides mutated | 06-04-2009 |
20090202552 | GENE EXPRESSED IN PROSTATE CANCER AND METHODS OF USE - A new polypeptide is disclosed that is specifically detected in the cells of the prostate, termed Novel Gene Expressed in Prostate (NGEP). Polynucleotides encoding NGEP are also disclosed, as are vectors including these polynucleotides. Host cells transformed with these polynucleotides are also disclosed. Antibodies are disclosed that specifically bind NGEP. Methods are disclosed for using an NGEP polypeptide, an antibody that specifically binds NGEP, or a polynucleotide encoding NGEP. Assays are disclosed for the detection prostate cancer. Pharmaceutical compositions including an NGEP polypeptide, an antibody that specifically binds NGEP, or a polynucleotide encoding NGEP are also disclosed. These pharmaceutical compositions are of use in the treatment of prostate cancer. | 08-13-2009 |
20090304702 | GENE EXPRESSED IN PROSTATE CANCER AND METHODS OF USE - A polypeptide is disclosed that is specifically detected in the cells of the prostate, termed Splice Variant-Novel Gene Expressed in Prostate (SV-NGEP). Polynucleotides encoding SV-NGEP are also disclosed, as are vectors including these polynucleotides. Host cells transformed with these polynucleotides are also disclosed. Antibodies and immunoconjugates are disclosed that specifically bind SV-NGEP. Methods are disclosed for using an NGEP polypeptide, an antibody that specifically binds SV-NGEP, or a polynucleotide encoding SV-NGEP. Assays are disclosed for the detection prostate cancer. Pharmaceutical compositions including an SV-NGEP polypeptide, an antibody that specifically binds SV-NGEP, or a polynucleotide encoding SV-NGEP are also disclosed. These pharmaceutical compositions are of use in the treatment of prostate cancer. | 12-10-2009 |
Patent application number | Description | Published |
20090035299 | Methods and compositions for treating diseases targeting MABA1 - Methods and compositions for diagnosing, detecting and treating a colon disease associated with differential expression of MABA1 in comparison to healthy cells. Also provided are antagonists or agonists of MABA1, and methods for screening agents that modulate the MABA1 level or activity in vivo or in vitro. | 02-05-2009 |
20090196873 | Methods and compositions for treating diseases targeting CDCP1 - Methods and compositions for detecting and treating a disease, particularly cancer, associated with differential expression of CDCP1 in disease cells compared to healthy cells. Also provided are antagonists or agonists of CDCP1, and methods for screening agents that modulate the CDCP1 level or activity in vivo or in vitro. | 08-06-2009 |
20100172908 | METHODS AND COMPOSITIONS FOR TREATING DISEASES TARGETING MABA1 - Methods and compositions for diagnosing, detecting and treating a colon disease associated with differential expression of MABA1 in comparison to healthy cells. Also provided are antagonists or agonists of MABA1, and methods for screening agents that modulate the MABA1 level or activity in vivo or in vitro. | 07-08-2010 |
20130177566 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING DISEASES - Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro. | 07-11-2013 |
20130315915 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING DISEASES - Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods. | 11-28-2013 |
20140193419 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING DISEASES - Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro. | 07-10-2014 |
20140314768 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING DISEASES - Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro. | 10-23-2014 |
Patent application number | Description | Published |
20100061977 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING DISEASES - Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro. | 03-11-2010 |
20110250204 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING DISEASES - Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods. | 10-13-2011 |
20120177659 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING DISEASES - Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro. | 07-12-2012 |
Patent application number | Description | Published |
20090092632 | Methods for preparing complex multivalent immunogenic conjugates - Methods for preparing complex multivalent immunogenic conjugates that include simultaneously reacting a plurality or immunogenic-distinct polysaccharides with at least one protein to make the complex multivalent immunogenic conjugates. The simultaneous reaction involves reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. | 04-09-2009 |
20100266625 | Meningococcal and Pneumococcal Conjugate Vaccine and Method of Using Same - This disclosure relates to vaccine formulations comprising an immunogenic composition for inducing antibodies to both | 10-21-2010 |
20120009213 | Meningococcal And Pneumococcal Conjugate Vaccine And Method Of Using Same - This disclosure relates to vaccine formulations comprising an immunogenic composition for inducing antibodies to both | 01-12-2012 |
20120076817 | POLYSACCHARIDE-PROTEIN CONJUGATE VACCINES - Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification process can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products. | 03-29-2012 |
20120195922 | METHODS FOR PREPARING COMPLEX MULTIVALENT IMMUNOGENIC CONJUGATES - Methods for preparing complex multivalent immunogenic conjugates that include simultaneously reacting a plurality or immunogenic-distinct polysaccharides with at least one protein to make the complex multivalent immunogenic conjugates. The simultaneous reaction involves reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. | 08-02-2012 |
20140044748 | METHODS FOR PREPARING COMPLEX MULTIVALENT IMMUNOGENIC CONJUGATES - Methods for preparing complex multivalent immunogenic conjugates that include simultaneously reacting a plurality or immunogenic-distinct polysaccharides with at least one protein to make the complex multivalent immunogenic conjugates. The simultaneous reaction involves reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. | 02-13-2014 |
20140322258 | POLYSACCHARIDE-PROTEIN CONJUGATE VACCINES - Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification process can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products. | 10-30-2014 |
Patent application number | Description | Published |
20100215450 | Depth Gauge For Drill Bit - A depth gauge for use with a drill bit includes a body configured to receive a drill bit, a retention mechanism coupled to the body and configured to removably couple the body to the drill bit, and a cap configured to be removably coupled to the body. The cap can be coupled to the body in one of a first position relative to the body where the cap contacts a workpiece surface to prevent the drill bit from entering the workpiece more than a first depth, and a second position relative to the body where the cap contacts the workpiece surface to prevent the drill bit from entering the workpiece more than a second depth that is different from the first depth. | 08-26-2010 |
20100260565 | Depth Gauge For Drill Bit - A drill bit has a shank portion having a plurality of SDS-type slots, a cutting portion comprising at least one cutting flute, and an intermediate portion connecting the shank to the cutting portion, the intermediate portion including at least one additional slot. A depth gauge includes a body configured to receive the drill bit, a retention mechanism coupled to the body and having an inward projection to removably couple the body to the at least one additional slot in the drill bit, and a cap coupled to the body such that the cap contacts a workpiece surface to prevent the drill bit from entering the workpiece more than a predetermined depth, wherein the cap is movable relative to the body among a plurality of positions, wherein each of the plurality of positions corresponds to a different predetermined drilling depth. | 10-14-2010 |
20110048988 | Method And Package For Displaying Magnetic Tool Container - A display package includes a blister assembly and a storage container. The blister assembly includes a front blister surface having a first opening therein and a rear blister surface coupled to the front blister surface and defining a first cavity. The storage container includes a first container portion secured within the first cavity, a second container portion hingedly coupled to the first container portion for pivotal displacement between an open position and a closed position, and a magnet fixed to an outer surface of the second container portion. The magnet is located at or beyond an outer perimeter of the blister assembly when the first container portion is secured within the first cavity. The magnet is configured to secure the display package to a metallic structure. | 03-03-2011 |
20110081214 | Dust Collector for use with Drill Bit or Drill Bit Depth Stop - A dust collector is disclosed for use with a drill bit or a depth stop that is coupled to a drill bit. The dust collector includes a rear attachment portion configured to be axially fixed to a drill bit or to a drill bit depth stop that is axially fixed to a drill bit. An intermediate non-collapsible portion is attached to a front end of the rear attachment portion. The intermediate non-collapsible portion defines a dust-collecting pocket and is structured to inhibit collapse as the drill bit is inserted into a workpiece. A front collapsible portion is attached to a front end of the intermediate non-collapsible portion and at least partially collapses as the drill bit is inserted into a workpiece. | 04-07-2011 |
20120211951 | OSCILLATING TOOL ATTACHMENT FEATURE - A clamp arrangement for securing an accessory to an oscillating power tool can include a clamp assembly including a first clamp member that moves relative to the accessory between a closed position wherein the clamp assembly retains the accessory and an open position wherein the first clamp is offset from the accessory permitting removal of the first accessory from the clamp assembly. The clamp assembly can further comprise a second clamp member having a first portion that opposes the first clamp member and cooperates with the first clamp member to clamp the accessory between the first and second clamp members. An attachment plate can carry the clamp assembly. The attachment plate can have a first mating detail formed thereon that is configured to selectively and removably mate with a complementary second mating detail on the power tool in an assembled position. | 08-23-2012 |
20120267374 | Method and Package for Displaying Magnetic Tool Container - A display package includes a blister assembly and a storage container. The blister assembly includes a front blister surface having a first opening therein and a rear blister surface coupled to the front blister surface and defining a first cavity. The storage container includes a first container portion secured within the first cavity, a second container portion hingedly coupled to the first container portion for pivotal displacement between an open position and a closed position, and a magnet fixed to an outer surface of the second container portion. The magnet is located at or beyond an outer perimeter of the blister assembly when the first container portion is secured within the first cavity. The magnet is configured to secure the display package to a metallic structure. | 10-25-2012 |
20130154205 | Right Angle Attachment For Power Tools - A right angle attachment for use with a power tool that includes a housing having a handle portion and a gear case attached to the handle portion and supporting first and second right angle gears wherein the first right angle gear is driven by an input shaft that is connected to the drill and the second right angle gear has an opening therein for receiving a hex bit directly therein. A floating magnet head can surround the hex bit to aid in fastener retention and can be movable out of proximity of the hex bit to facilitate easy removal of the hex bit for replacement. An additional magnet can be disposed within the gear case at the base of the hex bit in order to magnetize the hex bit and further enhance the retention of the fastener therein. | 06-20-2013 |
20130220086 | Quick Change Bit Holder With Ring Magnet - A bit holder assembly for a rotary hand or powered tool, includes a body having a hex shank at its rearward end and a retraction collar slidably disposed on the body. The body has a coaxial hex socket formed therein to allow a tool bit to be inserted thereinto. A coil spring biases the retraction collar forwardly and biases a retaining clip toward the bottom of an angular slot formed in the body. The bit is removed by sliding the retraction collar rearwardly, to compress the coil spring and allow the retaining clip to retract back up the slot. A ring magnet is disposed at the forward end of the retraction collar to magnetize a fastener to retain the fastener to the bit. | 08-29-2013 |
20130328276 | Quick Change Bit Holder With Ring Magnet - A bit holder assembly for a rotary hand or powered tool, includes a body having a hex shank at its rearward end and a retraction collar slidably disposed on the body. The body has a coaxial hex socket formed therein to allow a tool bit to be inserted thereinto. A coil spring biases the retraction collar forwardly and biases a retaining clip toward the bottom of an angular slot formed in the body. The bit is removed by sliding the retraction collar rearwardly, to compress the coil spring and allow the retaining clip to retract back up the slot. A ring magnet is disposed at the forward end of the retraction collar to magnetize a fastener to retain the fastener to the bit. | 12-12-2013 |
Patent application number | Description | Published |
20100252293 | Ergonomic Handle for Power Tool - An ergonomic handle for use with a power tool defines a first region that includes a switch, adapted to receive a thumb and forefinger when the forefinger is actuating the switch, a second region adapted to receive a middle finger, a third region adapted to receive a ring finger; and a fourth region adapted to receive a pinky finger. Each of the second, third, and fourth region includes a generally oval cross section having a major axis and a minor axis. The longest major axis is in the third region, the shortest major axis is in the fourth region, the shortest minor axis is in the second region, and the longest minor axis is positioned in the fourth region. | 10-07-2010 |
20130032010 | Ergonomic Handle for Power Tool - An ergonomic handle for use with a power tool defines a first region that includes a switch, adapted to receive a thumb and forefinger when the forefinger is actuating the switch, a second region adapted to receive a middle finger, a third region adapted to receive a ring finger; and a fourth region adapted to receive a pinky finger. Each of the second, third, and fourth region includes a generally oval cross section having a major axis and a minor axis. The longest major axis is in the third region, the shortest major axis is in the fourth region, the shortest minor axis is in the second region, and the longest minor axis is positioned in the fourth region. | 02-07-2013 |
Patent application number | Description | Published |
20080259340 | AIRBORNE TUNABLE MID-IR LASER GAS-CORRELATION SENSOR - A method and apparatus for measuring target gas concentrations in an atmosphere. The method and apparatus emit in the atmosphere a laser beam tuned to a molecular absorption line of a target gas, receive a reflected signal affected by gas absorption of the target gas in the atmosphere, divide and direct the received signal into a first optical path and a second optical path including in one of the paths a correlation gas cell filled with a predetermined concentration of the target gas, detect transmitted signals through the first optical path and the second optical path, and calculate a target gas concentration by comparing a first signal transmitted through the first optical path to a second signal transmitted through the second optical path. The apparatus includes a laser source tunable to a specific molecular absorption line of a target gas and configured to emit in the atmosphere a laser beam having a spectral bandwidth greater than a full width of the molecular absorption line of the target gas, a receiver configured to receive a reflected signal affected by gas absorption of the target gas in the atmosphere, and at least one detector configured to detect transmitted signals through the first optical path and the second optical path. | 10-23-2008 |
20100006760 | Ultraviolet lidar for detection of biological warfare agents - A system and method for detecting airborne agents. The system includes a semiconductor ultraviolet optical source configured to emit an ultraviolet light, a controller configured to generate a pseudo-random code for emission of the ultraviolet light modulated at the pseudo-random code, a telescope configured to focus the ultraviolet light to a distance from the source and to receive elastically backscattered signals and fluorescence signals from the distance, and a sensor configured to detect the elastically backscattered and fluorescence signals. The method generates a pseudo-random code and emits at least one wavelength of ultraviolet light modulated at the pseudo-random code, transmits the modulated ultraviolet light pulses to a distance from the source, receives elastically backscattered signals and fluorescence signals from the distance, and detects the elastically backscattered and fluorescence signals. | 01-14-2010 |
20100163733 | AIRBORNE TUNABLE MID-IR LASER GAS-CORRELATION SENSOR - A method and apparatus for measuring target gas concentrations in an atmosphere. The method and apparatus emit in the atmosphere a laser beam tuned to a molecular absorption line of a target gas, receive a reflected signal affected by gas absorption of the target gas in the atmosphere, divide and direct the received signal into a first optical path and a second optical path including in one of the paths a correlation gas cell filled with a predetermined concentration of the target gas, detect transmitted signals through the first optical path and the second optical path, and calculate a target gas concentration by comparing a first signal transmitted through the first optical path to a second signal transmitted through the second optical path. The apparatus includes a laser source tunable to a specific molecular absorption line of a target gas and configured to emit in the atmosphere a laser beam having a spectral bandwidth greater than a full width of the molecular absorption line of the target gas, a receiver configured to receive a reflected signal affected by gas absorption of the target gas in the atmosphere, and at least one detector configured to detect transmitted signals through the first optical path and the second optical path. | 07-01-2010 |
Patent application number | Description | Published |
20100239923 | Photobiological hydrogen production with switchable photosystem-II designer algae - A process for enhanced photobiological H | 09-23-2010 |
20100330637 | Designer Organisms for Photobiological Butanol Production from Carbon Dioxide and Water - The present invention provides a biosafety-guarded photobiological butanol production technology based on designer transgenic plants, designer algae, designer blue-green algae (cyanobacteria and oxychlorobacteria), or designer plant cells. The designer photosynthetic organisms are created such that the endogenous photobiological regulation mechanism is tamed, and the reducing power (NADPH) and energy (ATP) acquired from the photosynthetic process are used for synthesis of butanol (CH | 12-30-2010 |
20100330639 | Designer Oxyphotobacteria and Greenhouse Distillation for Photobiological Ethanol Production from Carbon Dioxide and Water - The present invention provides a photobiological ethanol production and harvesting technology using greenhouse distillation systems with designer photosynthetic organisms, such as designer transgenic oxyphotobacteria. The designer oxyphotobacteria are created such that the endogenous photobiological regulation mechanism is tamed, and the reducing power (NADPH) and energy (ATP) acquired from the photosynthetic process are used for synthesis of ethanol (CH | 12-30-2010 |
20110120854 | PHOTOVOLTAIC PANEL-INTERFACED SOLAR-GREENHOUSE DISTILLATION SYSTEMS - A hybrid photovoltaic panel-interfaced solar-greenhouse distillation technology is provided that is capable of utilizing solar waste heat to perform liquid distillation while co-generating solar electricity. Solar waste heat co-generated at a photovoltaic panel is effectively utilized by in situ distillation liquid as an immediate heat sink in thermo contact with the photovoltaic panel front surface, thus providing beneficial cooling of the photovoltaic panel and co-making of distillation products while generating electricity with significant improvement on total-process solar energy utilization efficiency. Its enabled beneficial utilization of waste heat can provide a series of distillation-related products such as: freshwater, sea salts, distilled water, hot water, hot steam, saline/brine products, and brine photobiological cultures for production of advanced biofuels and bioproducts, in addition to solar electricity. | 05-26-2011 |
20110177571 | DESIGNER CALVIN-CYCLE-CHANNELED PRODUCTION OF BUTANOL AND RELATED HIGHER ALCOHOLS - Designer Calvin-cycle-channeled and photosynthetic NADPH-enhanced pathways, the associated designer genes and designer transgenic photosynthetic organisms for photobiological production of butanol and related higher alcohols from carbon dioxide and water are provided. The butanol and related higher alcohols include 1-butanol, 2-methyl-1-butanol, isobutanol, 3-methyl-1-butanol, 1-hexanol, 1-octanol, 1-pentanol, 1-heptanol, 3-methyl-1-pentanol, 4-methyl-1-hexanol, 5-methyl-1-heptanol, 4-methyl-1-pentanol, 5-methyl-1-hexanol, and 6-methyl-1-heptanol. The designer photosynthetic organisms such as designer transgenic oxyphotobacteria and algae comprise designer Calvin-cycle-channeled and photosynthetic NADPH-enhanced pathway gene(s) and biosafety-guarding technology for enhanced photobiological production of butanol and related higher alcohols from carbon dioxide and water. | 07-21-2011 |
20110256613 | Designer proton-channel transgenic algae for photobiological hydrogen production - A designer proton-channel transgenic alga for photobiological hydrogen production that is specifically designed for production of molecular hydrogen (H | 10-20-2011 |
20120298499 | PHOTOVOLTAIC PANEL-INTERFACED SOLAR-GREENHOUSE DISTILLATION SYSTEMS - A hybrid photovoltaic panel-interfaced solar-greenhouse distillation technology is disclosed that is capable of utilizing solar waste heat to perform liquid distillation while co-generating solar electricity. Solar waste heat co-generated at a photovoltaic panel is effectively utilized by in situ distillation liquid as an immediate heat sink in thermal contact with the photovoltaic panel, thus providing beneficial cooling of the photovoltaic panel and co-making of distillation products while generating electricity with significant improvement on total-process solar energy utilization efficiency. Use of this invention can provide a series of distillation-related products such as freshwater, distilled water, hot water, hot steam, sea salts, saline/brine products, and/or harvest biofuels and bioproducts such as ethanol from renewable resources while co-generating solar electricity. | 11-29-2012 |
20130344553 | Designer Calvin-Cycle-Channeled and Hydrogenotrophic Production of Butanol and Related Higher Alcohols - Designer Calvin-cycle-channeled and hydrogenotrophic biofuel-production pathways, the associated designer genes and designer transgenic organisms for autotrophic production of butanol and related higher alcohols from carbon dioxide, hydrogen, and/or water are provided. The butanol and related higher alcohols include 1-butanol, 2-methyl-1-butanol, isobutanol, 3-methyl-1-butanol, 1-hexanol, 1-octanol, 1-pentanol, 1-heptanol, 3-methyl-1-pentanol, 4-methyl-1-hexanol, 5-methyl-1-heptanol, 4-methyl-1-pentanol, 5-methyl-1-hexanol, and 6-methyl-1-heptanol. The designer autotrophic organisms such as designer transgenic oxyphotobacteria and algae comprise designer Calvin-cycle-channeled and hydrogenotrophic pathway gene(s) and biosafety-guarding technology for enhanced autotrophic production of butanol and related higher alcohols from carbon dioxide and water. | 12-26-2013 |
Patent application number | Description | Published |
20080226611 | Gene Therapy Using TGF-beta - The subject invention is related to a cell-mediated gene therapy treatment for orthopedic disease using a member belonging to the transforming growth factor-β (TGF-β) superfamily. TGF-β gene therapy as a new treatment method for degenerative arthritis is demonstrated. After transfection of TGF-β cDNA expression vectors into fibroblasts (NIH 3T3-TGF-β1), the cells were injected into rabbit achilles tendon and knee joints with artificially-made cartilage defects. Intratendinous injections were performed to determine the optimal concentration for in vivo expression. Partially defected cartilage model was made to simulate degenerative arthritis of the knee joint. The partial cartilage defect treated with the cell-mediated gene therapy procedure was covered by newly formed hyaline cartilage which indicates that the cells survived and stimulated matrix formation in this area. Completely denuded cartilage areas were covered by fibrous collagen. | 09-18-2008 |
20080279832 | OSTEOGENIC DIFFERENTIATION OF PREOSTEOBLASTIC CELLS - The application discloses a method for making bone at a bone defect site which includes generating a member of a transforming growth factor superfamily of proteins; generating a population of cultured connective tissue cells that may contain a vector encoding a gene, or a population of cultured connective tissue cells that do not contain any vector encoding a gene; and transferring the protein and the connective tissue cells of to the bone defect site, and allowing the bone defect site to make the bone. | 11-13-2008 |
20090238806 | TREATMENT OF INTERVERTEBRAL DISC DEGENERATION - The present application discloses a method for preventing or retarding degeneration of intervertebral disc at an intervertebral disc defect site, which includes injecting a mammalian connective tissue cell into the intervertebral disc defect site. | 09-24-2009 |
20100316612 | PRIMED CELL THERAPY - The subject invention is directed to a composition comprising primed connective tissue cells and a pharmaceutically acceptable carrier thereof. | 12-16-2010 |
20110229445 | METHOD FOR HEALING BONE FRACTURE USING TRANSFECTED CHONDROCYTES - The application discloses a method for making bone at a bone defect site for a person suffering from low bone mass which includes inserting a gene encoding a protein having bone regenerating function into a connective tissue cell operably linked to a promoter, and transplanting the mammalian cell into the bone defect site, and allowing the bone defect site to make the bone. | 09-22-2011 |
Patent application number | Description | Published |
20110076693 | METHOD FOR DETECTION AND QUANTIFICATION OF PLK1 EXPRESSION AND ACTIVITY - Isolated peptide substrates of Plk1 and nucleic acids encoding these peptides are disclosed. The peptides include two to ten repeats of the amino acid sequence set forth as X | 03-31-2011 |
20120065146 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE - Found in various eukaryotic organisms, polo-like kinases (collectively, Plks) are a conserved subfamily of Ser/Thr protein kinases that play critical roles in cell proliferation. Provided herein are compounds that specifically inhibit the activity of Plks, specifically Plk1. Further provided herein are methods for use of the compounds for the treatment of hyperproliferative disorders, particularly cancer. Also provided are uses of the compounds for the preparation of a medicament. | 03-15-2012 |
20140142044 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE - Novel compounds are provided that bind to polo-like kinases through the polo-box domain. In certain embodiments, the novel compounds are PEGylated peptides. The PEGylated peptides in accordance with the invention demonstrate high PBD-binding affinity. In certain embodiments, the PEGylated peptides have also achieved activities in whole cell systems. The invention also provides compounds that bind polo-like kinases through the polo-box domain and possess reduced anionic charge. Further provided are methods of design and/or synthesis of the PEGylated peptides and methods of use thereof. The invention provides methods of use of the compounds and methods of synthesis of the compounds. The compounds of the invention have potential therapeutic activity in view of their binding and inhibitory activities towards Plk1. They are based on the amino acid sequence PLHSpT (phosphorylated Thr). The PEG moiety, when present, is covalently attached at the N-terminus. The invention also encompasses derivatives having substituents on the Pro and/or the His side chains, substituents on the phosphate group, the replacement of His with Gln, the replacement of Pro with a N-substituted Gly, the replacement of Ser with Ala, as well as HS-pT fragments with N-terminal alkoxycarbonyl group and PLHS fragments with a C-terminal glyco-imino-alkylxyalkylamide group. | 05-22-2014 |
Patent application number | Description | Published |
20110077386 | NOVEL LIVER-TARGETING AGENTS AND THEIR SYNTHESIS - This invention provides novel liver targeting agents and their synthetic methods. A liver targeting agent, with a lysine based nitrilo triacetic acid structure as backbone which acquires multivalency with saccharide groups, to bind with a galactosamine chain or lactose chain is disclosed. In particular, only one amino acid L-lysine is involved to provide trivalency. All carboxyl groups in N | 03-31-2011 |
20110097264 | RADIOLABELING METHOD USING MULTIVALENT GLYCOLIGANDS AS HEPATIC RECEPTOR IMAGING AGENT - A radiolabeling method using a multivalent glycoligand as hepatic receptor imaging agent is provided. The multivalent glycoligand-DTPA derivatives (In-111-DTPA-hexa lactoside and In-111-DTPA-tri-galactosamine glycoside) labeled with In-111 are used as hepatic receptor imaging agent. The effects of imaging of a hepatic receptor in different species are evaluated, the lowest specific radioactivity values of hepatic receptor imaging required in different species are discovered. Since the specificity of the human ASGPR closely resembles that of the mouse. This kind of radiolabelling method, agent and related study about specific radioactivity could be used in clinical trial in the future. | 04-28-2011 |
20110097265 | QUANTIFICATION METHOD FOR REMAINING LIVER FUNCTION AND NOVEL LIVER RECEPTOR IMAGING AGENT - A test indicator for quantifying remaining liver function is provided. A novel liver receptor imaging agent with liver targeting property is utilized to develop a method for quantifying remaining liver function to serve as test indicator for judging the liver failure outcome in clinic, particularly for judging the necessity of liver transplantation for patients with liver failure or liver disease. The radioactivity uptake of the test indicator was negatively correlated with the extent of liver reserve. The cutoff value of liver reserve for liver transplantation is also disclosed. | 04-28-2011 |
20130225798 | QUANTIFICATION METHOD FOR REMAINING LIVER FUNCTION AND NOVEL LIVER RECEPTOR IMAGING AGENT - A test indicator for quantifying remaining liver function is provided. A novel liver receptor imaging agent with liver targeting property is utilized to develop a method for quantifying remaining liver function to serve as test indicator for judging the liver failure outcome in clinic, particularly for judging the necessity of liver transplantation for patients with liver failure or liver disease. The radioactivity uptake of the test indicator was negatively correlated with the extent of liver reserve. The cutoff value of liver reserve for liver transplantation is also disclosed. | 08-29-2013 |
Patent application number | Description | Published |
20080220192 | MULTILAYER STRUCTURES OF POLY(1,3 PROPYLENE 2,6-NAPHTHALATE) AND POLY(ETHYLENE TEREPHTHALATE) - Multilayer shaped articles, including films, preforms and containers, and method for forming the same, having at least one layer of poly(l, 3-propylene 2,6-naphthalate) and at least one layer of poly(ethylene terephthalate). Poly(1,3-propylene 2,6-naphthalate) can be co-stretched with poly(ethylene terephthalate) to form oriented multilayer structures which have superior barrier properties. The poly(l,3-propylene 2,6-naphthalate) and poly(ethylene terephthalate) layers have good adhesion and do not require an adhesive tie layer. | 09-11-2008 |
20140331841 | COMPLIANT OR ROLLABLE CUTTING SURFACE AND CUTTING DEVICE - A cutting apparatus for hair or fiber protruding from a surface includes a roller, a number of cutting features disposed at an outer peripheral surface of the roller, wherein the number of cutting features is adapted for cutting the hair or fiber when the roller rotates in contact with the filamentous surface or is moved while in contact with the filamentous surface. | 11-13-2014 |
20150059729 | PACKAGE FOR OXYGEN ACTIVATED PORTABLE HEATER - Improvements for packages for oxygen based portable heaters, including improvements relating to packaging forms, reactant control, thermal control, heat initiation, graphics on the package, and integrated packaging structures. | 03-05-2015 |
Patent application number | Description | Published |
20090108252 | Lateral two-terminal nanotube devices and method for their formation - An apparatus, system, and method are provided for a lateral two-terminal nanotube device configured to capture and generate energy, to store electrical energy, and to integrate these functions with power management circuitry. The lateral nanotube device can include a substrate, an anodic oxide material disposed on the substrate, and a column disposed in the anodic oxide material extending from one distal end of the anodic oxide material to another end of the anodic oxide material. The lateral nanotube device further can include a first material disposed within the column, and a second material disposed within the column. The first material fills a distal end of the column and gradiently decreases towards another distal end of the column along inner walls of the column. The second material fills the another distal end of the column and gradiently decreases towards the distal end of the column within the first material. | 04-30-2009 |
20100266897 | High-Powered Electrochemical Energy Storage Devices and Methods for Their Fabrication - The present invention relates to electrochemical storage devices, such as supercapacitors, batteries, etc., and more particularly to such devices that comprise an electrochemically active coaxial nanowire. The invention particularly concerns such devices in which the coaxial nanowire comprises an inner core of a transition metal oxide and an axially surrounding outer shell composed of an electroconductive organic polymer, such as poly(3,4-ethylenedioxythiophene) (PEDOT). The invention particularly relates to a facile method for achieving the self-assembly of such coaxial nanowires. | 10-21-2010 |
20110073827 | NANODEVICE ARRAYS FOR ELECTRICAL ENERGY STORAGE, CAPTURE AND MANAGEMENT AND METHOD FOR THEIR FORMATION - An apparatus, system, and method are provided for a vertical two-terminal nanotube device configured to capture and generate energy, to store electrical energy, and to integrate these functions with power management circuitry. The vertical nanotube device can include a column disposed in an anodic oxide material extending from a first distal end of the anodic oxide material to a second distal end of the anodic oxide material. Further, the vertical nanotube device can include a first material disposed within the column, a second material disposed within the column, and a third material disposed between the first material and the second material. The first material fills the first distal end of the column and extends to the second distal end of the column along inner walls of the column. The second material fills the first distal end of the column and extends to the second distal end of the column within the first material. Both the first material and the second material are exposed at the first distal end of the column. | 03-31-2011 |
Patent application number | Description | Published |
20120192237 | METHOD AND APPARATUS FOR PROVIDING PREAUTHORIZATION FOR A MOBILE RECEIVING DEVICE TO ACCESS WIRELESS NETWORKS - A mobile wireless system includes a transmitter such as a satellite that broadcasts wireless signals such as boundaries for wireless networks to a mobile receiving device. Mobile receiving device may include an antenna. A locating receiver is used to generate locating signals so that a determination may be made to the location of the mobile receiving device. Preauthorizations may be obtained to allow the mobile receiving device to communicate back to business controller to enable functions such as pay-per-view or on-demand, interactive television, gaming, and the like. The preauthorizations enable access to various wireless networks as the mobile receiving device moves. | 07-26-2012 |
20130174192 | METHOD AND SYSTEM FOR DETECTING UNAUTHORIZED USE OF A SET TOP BOX USING WEATHER PROFILES - A system and method for determining unauthorized use of a set top box includes a set top box that receives a profile of weather conditions in a geographic area, generating a weather log, comparing the weather log and the profile and disabling the set top box from receiving signals in response to comparing. A head end and a plurality of other set top boxes may be used to gather the weather data to form the profile. | 07-04-2013 |
20130212616 | METHOD AND SYSTEM FOR CONFIGURING A USER INTERFACE OF A RECEIVING UNIT FOR AN AUXILIARY REMOTE CONTROL DEVICE - A system and method for controlling a user interface comprises an auxiliary remote control device having an auxiliary remote control device identifier associated therewith and a receiving unit comprising a filter module having a filter feature for filtering content data from a set of available content data in response to an auxiliary remote control device identifier received at the receiving unit. The filter module forms filtered available content data less than the set of available content data. The receiving unit displays the user interface having the filtered available content data associated with the auxiliary remote control device on a display associated with the receiving unit. | 08-15-2013 |
20140071161 | METHOD AND SYSTEM FOR COMMUNICATING BETWEEN A HOST DEVICE AND USER DEVICE THROUGH AN INTERMEDIATE DEVICE USING A COMPOSITE VIDEO SIGNAL - A system and method includes a host device using a first format, an intermediate device, a user device using a second format and a network in communication with the host device, the intermediate device and the user device. The user device communicates a first user generated signal having the second format to the intermediate device. The intermediate device converts the second format of the first user generated signal to the first format to form a second user generated signal. The intermediate device communicates the second user generated signal to the host device. | 03-13-2014 |
20140075485 | METHOD AND SYSTEM FOR COMMUNICATING BETWEEN A HOST DEVICE AND A USER DEVICE THROUGH AN INTERMEDIATE DEVICE USING A COMPOSITE GRAPHICS SIGNAL - A system and method includes a host device, an intermediate device and a user device. A network is in communication with the host device, the intermediate device and the user device. The host device communicates a first graphics command and a second graphics command to the intermediate device. The intermediate device composites the first graphics command and the second graphics command to form a composite graphics command and communicating the composite graphics command to the user device. The user device generates a screen display in response to the composite graphics command. | 03-13-2014 |
20140075486 | METHOD AND SYSTEM FOR COMMUNICATING BETWEEN A HOST DEVICE AND USER DEVICE THROUGH AN INTERMEDIATE DEVICE USING SYNTAX TRANSLATION - A system and method includes a host device, an intermediate device and a user device having a device type associated therewith. A network is in communication with the host device, the intermediate device and the user device. The host device communicates a first graphics command to the intermediate device. The intermediate device converts the first graphics command to a second graphics command in response to the device type. The user device generates a screen display in response to the second graphics command. | 03-13-2014 |
20140075576 | METHOD AND SYSTEM FOR AUTHORIZING PLAYBACK FROM MULTIPLE DEVICES - A system and method for using content on multiple devices includes a head end associating a first user device and a second user device with a user account and authorizing the first user device and the second user device to receive content. The first user device forms a selection signal corresponding to a first content. The head end communicates the first content to the first user device corresponding to the selection signal. The first user device displays the first content on a first display associated therewith. The second user device receives the first content and displays the first content on a second display associated with the second user device. | 03-13-2014 |
20140130106 | METHOD AND SYSTEM FOR REMOTELY TRANSCODING CONTENT - A system and method for remotely transcoding content includes a set top box generating a playlist corresponding to content titles stored in a memory of the set top box. A user device is in communication with the cloud location and the set top box through a network. The user device reviews the playlist and selects a first content title from the playlist to form a selection. The cloud location includes a transcoder device transcoding content corresponding to the selection to form transcoded content. One of the cloud location and the set top box communicates the transcoded content to the user device. | 05-08-2014 |
20140282749 | METHOD AND SYSTEM FOR TRANSFERRING USER SETTINGS TO ANOTHER USER RECEIVING DEVICE - A system and method for operating a user receiving device includes a head end associating a first user device with a user account having first user settings. A first user device communicates a device identifier associated with the user receiving device to the head end. The head end communicates the first user settings associated with the user account to the user receiving device. The user receiving device operates with the first user settings. | 09-18-2014 |
20140282807 | METHOD AND SYSTEM FOR TRANSFERRING USER SETTINGS TO ANOTHER USER RECEIVING DEVICE USING A MOBILE USER DEVICE - A system and method for operating a user receiving device includes a first user device that receives first user settings and stores the first user settings therein. The first user device communicates first user settings to a second user receiving device. The second user receiving device operates with the first user settings. | 09-18-2014 |
20140310737 | METHOD AND SYSTEM FOR AUTHORIZING PLAYBACK FROM MULTIPLE DEVICES - A system and method for using content on multiple devices includes a head end associating a first user device and a second user device with a user account and authorizing the first user device and the second user device to receive content. The first user device forms a selection signal corresponding to a first content. The head end communicates the first content to the first user device corresponding to the selection signal. The first user device displays the first content on a first display associated therewith. The second user device receives the first content and displays the first content on a second display associated with the second user device. | 10-16-2014 |
20150040150 | METHOD AND SYSTEM FOR REMOTELY TRANSCODING CONTENT - A system and method for remotely transcoding content includes a set top box generating a playlist corresponding to content titles stored in a memory of the set top box. A user device is in communication with the cloud location and the set top box through a network. The user device reviews the playlist and selects a first content title from the playlist to form a selection. The cloud location includes a transcoder device transcoding content corresponding to the selection to form transcoded content. One of the cloud location and the set top box communicates the transcoded content to the user device. | 02-05-2015 |
Patent application number | Description | Published |
20120078773 | Method and System for Calculating an Intraday Indicative Value of Leveraged Bullish and Bearish Exchange Traded Funds - A computer implemented method, system, and software for calculating and using an intraday indicative value of a leveraged Bullish or Bearish exchange traded fund (“ETF”) for arbitrage purposes, includes calculating an intraday current value of all the equity securities in the ETF (applicable only to Bullish ETFs), calculating mark to market gains or losses of at least one derivative product, and retrieving an accumulated loss or gain of the at least one derivative product and other cash equivalent amounts. The intraday indicative value of the ETF is determined by combining the calculated intraday current value of all the equity securities (applicable only to Bullish ETFs), the accumulated loss or gain, the mark to market gains of the at least one derivative product and other cash equivalent amounts. The determined intraday value of the ETF is used, by a party, for arbitrage purposes. | 03-29-2012 |
20120078774 | Method and System for Calculating an Intraday Indicative Value of Leveraged Bullish and Bearish Exchange Traded Funds - A computer implemented method, system, and software for calculating and using an intraday indicative value of a leveraged Bullish or Bearish exchange traded fund (“ETF”) for arbitrage purposes, includes calculating an intraday current value of all the equity securities in the ETF (applicable only to Bullish ETFs), calculating mark to market gains or losses of at least one derivative product, and retrieving an accumulated loss or gain of the at least one derivative product and other cash equivalent amounts. The intraday indicative value of the ETF is determined by combining the calculated intraday current value of all the equity securities (applicable only to Bullish ETFs), the accumulated loss or gain, the mark to market gains of the at least one derivative product and other cash equivalent amounts. The determined intraday value of the ETF is used, by a party, for arbitrage purposes. | 03-29-2012 |
Patent application number | Description | Published |
20100124330 | Secure transmission over satellite phone network - A reach back secure communications terminal includes a modem to satellite interconnect board that captures DTMF tones, demodulates encrypted modem information, and converts both into an ASCII string for presentation to a data port of a satellite phone, allowing out-of-band control of a non-secure satellite system (e.g., AT command control of a data port) by a user on a secure side of an encryption device, by including the ability to interpret control signals and control the satellite system appropriately. A false dial tone is presented to the encryption device, and the data stream coming from the encryption device is monitored for the presence of dual-tone, multi-frequency (DTMF) tones representing control signals, the DTMF tones are converted to ASCII characters, which are in turn received as control signals by the satellite phone, allowing control of the functions of the satellite system directly from the secure side of the encryption device. | 05-20-2010 |
20110237247 | Secure transmission over satellite phone network - A reach back secure communications terminal includes a modem to satellite interconnect board that captures DTMF tones, demodulates encrypted modem information, and converts both into an ASCII string for presentation to a data port of a satellite phone, allowing out-of-band control of a non-secure satellite system (e.g., AT command control of a data port) by a user on a secure side of an encryption device, by including the ability to interpret control signals and control the satellite system appropriately. A false dial tone is presented to the encryption device, and the data stream coming from the encryption device is monitored for the presence of dual-tone, multi-frequency (DTMF) tones representing control signals, the DTMF tones are converted to ASCII characters, which are in turn received as control signals by the satellite phone, allowing control of the functions of the satellite system directly from the secure side of the encryption device. | 09-29-2011 |
Patent application number | Description | Published |
20090030021 | Quinazoline Derivatives and Therapeutic Use Thereof - Quinazoline derivatives represented by the general formula | 01-29-2009 |
20090270358 | PHARMACEUTICAL FORMULATION OF CLAVULANIC ACID - The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as potassium clavulanate or Clavitesse™, preferably in an immediate-release solid dosage form or an extended-release solid dosage form. Also provided are methods for making and using such immediate-release and stabilized compositions or extended-release and stabilized compositions. | 10-29-2009 |
20100099644 | HPMA - DOCETAXEL OR GEMCITABINE CONJUGATES AND USES THEREFORE - Disclosed are water-soluble compositions of gemcitabine and docetaxel formed by conjugating the gemcitabine or docetaxel to a water-soluble polymer such as N-2-hydroxypropyl methacrylamide (HPMA). Also disclosed are methods of using the compositions of the invention for the treatment of cancer. | 04-22-2010 |
20100255099 | CLAVULANATE FORMULATION FOR NEUROPROTECTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS - The present invention generally relates to use of a stable solid pharmaceutical compositions that includes a clavulanate as the pharmaceutically active ingredients in an immediate-release or an extended-release solid dosage form. The composition can be used in a method of treating a neurodegenerative disease, providing neuroprotection, or preventing neuronal cell loss or death. Exemplary neurodegenerative diseases include Parkinson's disease, Alzheimer's disease and multiple sclerosis. | 10-07-2010 |
20110086111 | POLYMERIC SYSTEMS FOR THE DELIVERY OF ANTICANCER DRUGS - The present invention relates to compositions for the treatment of cancerous tissues in warm-blooded animals containing one or two anticancer agents attached to polymeric carriers having monomer units derived from one or more of N-(2-carboxypropyl)methacrylamide (2-CPMA), N-(3-carboxypropyl)methacrylamide (3-CPMA), N-(2-aminopropyl)methacrylamide (2-APMA) and/or N-(3-aminopropyl)methacrylamide (3-APMA) are also included. Anticancer agents in compositions can be attached to said polymeric carrier by side-chains which can be susceptible to hydrolysis by lysosomal enzymes intracellularly. Compositions can also include a targeting ligand attached to the polymeric carrier, optionally through a second linker. | 04-14-2011 |
Patent application number | Description | Published |
20080318963 | 1-[6,7-Substituted Alkoxyquinoxalinyl) Aminocarbonyl]-4-(Hetero) Arylpiperazine Derivatives - The present invention relates to novel quinoxaline-piperazine compounds, 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives and their pharmaceutically acceptable salts, a process for their preparation thereof, and compositions containing such compounds. Therapeutic methods for the treatment of hyperproliferative disorders, including cancers, by administering quinoxalin-piperazine compounds are also included. | 12-25-2008 |
20130053390 | 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES - The present invention relates to novel quinoxaline-piperazine compounds, 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives and their pharmaceutically acceptable salts, a process for their preparation thereof, and compositions containing such compounds. Therapeutic methods for the treatment of hyperproliferative disorders, including cancers, by administering quinoxaline-piperazine compounds are also included. | 02-28-2013 |
Patent application number | Description | Published |
20110077386 | NOVEL LIVER-TARGETING AGENTS AND THEIR SYNTHESIS - This invention provides novel liver targeting agents and their synthetic methods. A liver targeting agent, with a lysine based nitrilo triacetic acid structure as backbone which acquires multivalency with saccharide groups, to bind with a galactosamine chain or lactose chain is disclosed. In particular, only one amino acid L-lysine is involved to provide trivalency. All carboxyl groups in N | 03-31-2011 |
20110097264 | RADIOLABELING METHOD USING MULTIVALENT GLYCOLIGANDS AS HEPATIC RECEPTOR IMAGING AGENT - A radiolabeling method using a multivalent glycoligand as hepatic receptor imaging agent is provided. The multivalent glycoligand-DTPA derivatives (In-111-DTPA-hexa lactoside and In-111-DTPA-tri-galactosamine glycoside) labeled with In-111 are used as hepatic receptor imaging agent. The effects of imaging of a hepatic receptor in different species are evaluated, the lowest specific radioactivity values of hepatic receptor imaging required in different species are discovered. Since the specificity of the human ASGPR closely resembles that of the mouse. This kind of radiolabelling method, agent and related study about specific radioactivity could be used in clinical trial in the future. | 04-28-2011 |
20110097265 | QUANTIFICATION METHOD FOR REMAINING LIVER FUNCTION AND NOVEL LIVER RECEPTOR IMAGING AGENT - A test indicator for quantifying remaining liver function is provided. A novel liver receptor imaging agent with liver targeting property is utilized to develop a method for quantifying remaining liver function to serve as test indicator for judging the liver failure outcome in clinic, particularly for judging the necessity of liver transplantation for patients with liver failure or liver disease. The radioactivity uptake of the test indicator was negatively correlated with the extent of liver reserve. The cutoff value of liver reserve for liver transplantation is also disclosed. | 04-28-2011 |
20130225798 | QUANTIFICATION METHOD FOR REMAINING LIVER FUNCTION AND NOVEL LIVER RECEPTOR IMAGING AGENT - A test indicator for quantifying remaining liver function is provided. A novel liver receptor imaging agent with liver targeting property is utilized to develop a method for quantifying remaining liver function to serve as test indicator for judging the liver failure outcome in clinic, particularly for judging the necessity of liver transplantation for patients with liver failure or liver disease. The radioactivity uptake of the test indicator was negatively correlated with the extent of liver reserve. The cutoff value of liver reserve for liver transplantation is also disclosed. | 08-29-2013 |
Patent application number | Description | Published |
20110178155 | SILENCING OF CSN5 GENE EXPRESSION USING INTERFERING RNA - The present invention provides compositions comprising nucleic acids that target CSN5 gene expression and methods of using such compositions to silence CSN5 gene expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence CSN5 gene expression and methods of use thereof, e.g., for treating cell proliferative disorders such as cancer. The present invention also provides nucleic acid-lipid particles that target CSN5 gene expression comprising an interfering RNA molecule, a cationic lipid, a non-cationic lipid, and optionally a conjugated lipid that inhibits aggregation of particles. | 07-21-2011 |
20130065939 | COMPOSITIONS AND METHODS FOR SILENCING GENES EXPRESSED IN CANCER - The present invention provides therapeutic nucleic acids such as interfering RNA (e.g., siRNA) that target the expression of genes associated with tumorigenesis and/or cell transformation, lipid particles (e.g., nucleic acid-lipid particles) comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles, e.g., for the treatment of a cell proliferative disorder such as cancer. | 03-14-2013 |
20130178511 | SILENCING OF CSN5 GENE EXPRESSION USING INTERFERING RNA - The present invention provides compositions comprising nucleic acids that target CSN5 gene expression and methods of using such compositions to silence CSN5 gene expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence CSN5 gene expression and methods of use thereof, e.g., for treating cell proliferative disorders such as cancer. The present invention also provides nucleic acid-lipid particles that target CSN5 gene expression comprising an interfering RNA molecule, a cationic lipid, a non-cationic lipid, and optionally a conjugated lipid that inhibits aggregation of particles. | 07-11-2013 |